65,437 trials
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) — 780; 717; 858 nanograms*hours/milliliter (ng*hr/mL)
Surgery
Primary: Intraoperative Distal Esophageal (Core) Temperature — 35.96; 35.87 °C — p=<0.0001
Diabetes Mellitus
Primary: Change From Baseline in A1C at Week 24 — -0.33; -0.45 Percent — p=0.535
Huntington Disease
Primary: Safety and Tolerability of PBT2 in Patients With HD — 32; 30; 28 participants
Venous Thromboembolic Disease · Deep Vein Thrombosis · Pulmonary Embolism
Primary: Lower Extremity Deep Vein Thrombosis — 4.8; 2.9 percentage of patients — p=0.025
Small Cell Lung Carcinoma
Primary: Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy — 10.97; 10.94 months — p=0.3775
Diabetes Mellitus, Type 1
Primary: Percentage of Participants With Hemoglobin A1c (HbA1c) Reduction Greater Than or Equal to (>=) 0.4 Percent (%) and no Increase in Body Weight — 14.5; 36.9; 41.4; 85.5…
Advanced Idiopathic Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Total Score, and UPDRS Subscores I, II, III, and IV at Baseline and Month 12 — 52.1; NA; NA; 42.5 units on a scale…
Head and Neck Cancer
Primary: Number of Participants With Any Adverse Device Effects Considered Attributable to AuroShell Particle Administration — 2; 2; 0 participants
Anemia
Primary: Percentage of Participants Who Achieved Hemoglobin Response up to Week 24 — 79.5; 87.8 Percentage of participants
Coronary Artery Disease · Angina Pectoris
Primary: Kaplan-Meier Estimates for Time From Randomization to First Occurrence of Ischemia-driven Revascularization or Ischemia-driven Hospitalization Without Revascularization…
Female Genital Diseases
Primary: Reduction in Daily Genital Pain. — 2.4; 2.92; 3.42; 2.77 units on a scale — p=0.30
Chronic Hepatitis · Chronic Hepatitis C · Chronic Alcoholic Hepatitis
Primary: The Change in Serum Alanine Aminotransferase Level From Baseline to 12 Weeks — 77.5; 105.5 IU/L
Breast Cancer
Primary: Objective Response Rate (as Determined by Investigator): the Percentage of Patients Assigned to a Treatment Arm With a Confirmed Best Response of CR or PR. — 0; 1; 1; 0…
Hepatitis D, Chronic
Primary: Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment…